Australia · Delayed Price · Currency is AUD PharmX Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 3% to AUD 3.9 million with strong Marketplace and New Zealand performance, positive EBITDA, and a major strategic partnership with Sigma Chemist Warehouse. Marketplace adoption and supplier integration surged, supporting future growth.
Fiscal Year 2025
-
FY 2025 delivered 13% revenue growth, strong platform expansion, and improved cash flow, despite higher investment. Marketplace and AI-driven initiatives are set to drive FY 2026 growth, with a stable cost base and robust market position.
-
Revenue grew 17% year-over-year, driven by strong performance in core and marketplace platforms, expansion into New Zealand, and new analytics offerings. Despite higher investment and a major legal settlement, profitability improved and the cash position remains strong.